Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Lemoyneon Aug 25, 2020 11:47am
220 Views
Post# 31450293

Australia increase in sales and exclusive license

Australia increase in sales and exclusive license"We already have the last quarter we got out 9000 products and this quarter were on target for around 30 to 40000 units"

"We are one of probably a couple of companies across the entire landscape Australia  to have all these licences so that really sort of this great great benefit now to the industry and also more importantly patients because one of the biggest sort of access stability issues is price point, the cost, so having a local products manufactured means that we can create something that's a fraction of the price that is the price coming from overseas after that and not only that obviously there rigour inequality around the product manufactured locally is different because of the regulatory environment in which we operate and so but a real big bonus of the industry here no less should essentially increased patient numbers because of the accessibility understanding cabinet but also more importantly the cost factor which have been tremendous hurdle for most normal people"

glta




https://mms.tveyes.com/MediaView/?c3RhdGlvbj0xMTYxNSZTdGFydERhdGVUaW1lPTA4JTJmMjQlMmYyMDIwKzA5JTNhNDIlM2E0MyZFbmREYXRlVGltZT0wOCUyZjI0JTJmMjAyMCswOSUzYTQ3JTNhMzkmJiZkdXJhdGlvbj0yOTk2NjAmcGFydG5lcmlkPTczMTMmJmhpZ2hsaWdodHJlZ2V4PSU1Y2JXYXJyZW4lNWNiJTdjJTVjYk1lZGlmYXJtJTVjYiU3YyU1Y2JsYWJzJTVjYiZtb2RlZGl0b3JlbmFibGU9dHJ1ZSZtb2RlZGl0b3JkZXN0aW5hdGlvbnM9NCYmZXhwaXJhdGlvbj0wOSUyZjIzJTJmMjAyMCswOSUzYTQyJTNhNDMuMDAwJmluc3RhbnRQbGF5PVRydWUmc2lnbmF0dXJlPWE2ZjgwMWM2ZjNmMTc1MjI1NGU4NjJmOTU3ZjA3ZDk2
<< Previous
Bullboard Posts
Next >>